Eurepa V 1/0.3 Tablet

Eurepa V 1/0.3 Tablet is an anti-diabetic medicine used to help control blood sugar levels in adults with Type 2 diabetes mellitus. It is a combination of Repaglinide (1 mg) and Voglibose (0.3 mg). Together, these medicines help reduce high blood sugar after meals and improve overall glycemic control when used along with proper diet and regular exercise.

Repaglinide works by stimulating the pancreas to release insulin, especially after food intake, while Voglibose slows the digestion and absorption of carbohydrates in the intestine. This dual action helps prevent sudden spikes in blood glucose levels after meals.

Key Benefits

• Helps control post-meal (post-prandial) blood sugar levels

• Supports better glycemic control in Type 2 diabetes

• Reduces the risk of diabetes-related complications when used as prescribed

• Works best when combined with healthy diet and lifestyle changes

How to Use
Take the tablet exactly as advised by your doctor, usually before meals. Do not skip meals after taking the dose. Do not self-adjust the dosage.

Safety Advice

• Not recommended for patients with Type 1 diabetes, diabetic ketoacidosis, severe kidney or liver disease (unless prescribed)

• Inform your doctor if you are pregnant, breastfeeding, or taking other medicines

• Monitor blood sugar levels regularly

• Watch for symptoms of low blood sugar such as dizziness, sweating, or weakness

Common Side Effects
Stomach discomfort, gas, diarrhea, nausea, headache, or mild hypoglycemia. Seek medical advice if symptoms persist or worsen.

Disclaimer: This description is for informational purposes only and not a substitute for professional medical advice. Always use this medicine under the supervision of a registered healthcare provider.